DDInter1628 DDInter100
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium. It is considered one of the most likely agents to be used in a biological attack. There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.[L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas around the world.
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Ruxolitinib {u} (Compound) downregulates {v} (Gene) ACADS
ACADS {u} (Gene) is upregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Ruxolitinib {u} (Compound) upregulates {v} (Gene) KIAA0753
KIAA0753 {u} (Gene) is upregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Ruxolitinib {u} (Compound) binds {v} (Gene) PHKG2
PHKG2 {u} (Gene) is upregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Ruxolitinib {u} (Compound) downregulates {v} (Gene) ABCB6
ABCB6 {u} (Gene) is downregulated by {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Ruxolitinib {u} (Compound) upregulates {v} (Gene) CHERP
CHERP {u} (Gene) is downregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Ruxolitinib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) DYRK1A
DYRK1A {u} (Gene) is downregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Ruxolitinib {u} (Compound) binds {v} (Gene) PLK4
PLK4 {u} (Gene) is downregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Ruxolitinib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) DYRK1A
DYRK1A {u} (Gene) is upregulated by {v} (Compound) Azacitidine
Azacitidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is palliated by {v} (Compound) Methylprednisolone
Methylprednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ruxolitinib (Compound) downregulates ACADS (Gene) and ACADS (Gene) is upregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ruxolitinib (Compound) upregulates KIAA0753 (Gene) and KIAA0753 (Gene) is upregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ruxolitinib (Compound) binds PHKG2 (Gene) and PHKG2 (Gene) is upregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ruxolitinib (Compound) downregulates ABCB6 (Gene) and ABCB6 (Gene) is downregulated by Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ruxolitinib (Compound) upregulates CHERP (Gene) and CHERP (Gene) is downregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ruxolitinib (Compound) binds DYRK1A (Gene) and Ruxolitinib (Compound) upregulates DYRK1A (Gene) and DYRK1A (Gene) is downregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ruxolitinib (Compound) binds PLK4 (Gene) and PLK4 (Gene) is downregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ruxolitinib (Compound) binds DYRK1A (Gene) and Ruxolitinib (Compound) upregulates DYRK1A (Gene) and DYRK1A (Gene) is upregulated by Azacitidine (Compound) and Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is palliated by Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine